You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

ZANAFLEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zanaflex patents expire, and when can generic versions of Zanaflex launch?

Zanaflex is a drug marketed by Legacy Pharma Usa and is included in two NDAs.

The generic ingredient in ZANAFLEX is tizanidine hydrochloride. There are eleven drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the tizanidine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zanaflex

A generic version of ZANAFLEX was approved as tizanidine hydrochloride by DR REDDYS LABS INC on July 3rd, 2002.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZANAFLEX?
  • What are the global sales for ZANAFLEX?
  • What is Average Wholesale Price for ZANAFLEX?
Drug patent expirations by year for ZANAFLEX
Drug Prices for ZANAFLEX

See drug prices for ZANAFLEX

Recent Clinical Trials for ZANAFLEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Henry Ford Health SystemPhase 4
National Center for Advancing Translational Science (NCATS)Phase 2
University of California, San DiegoPhase 2

See all ZANAFLEX clinical trials

Pharmacology for ZANAFLEX
Paragraph IV (Patent) Challenges for ZANAFLEX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZANAFLEX Capsules tizanidine hydrochloride 2 mg, 4 mg and 6 mg 021447 1 2007-08-10

US Patents and Regulatory Information for ZANAFLEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Legacy Pharma Usa ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-001 Aug 29, 2002 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Legacy Pharma Usa ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397-002 Feb 4, 2000 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Legacy Pharma Usa ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-002 Aug 29, 2002 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Legacy Pharma Usa ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-003 Aug 29, 2002 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Legacy Pharma Usa ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397-001 Nov 27, 1996 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZANAFLEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Legacy Pharma Usa ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-001 Aug 29, 2002 ⤷  Sign Up ⤷  Sign Up
Legacy Pharma Usa ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-003 Aug 29, 2002 ⤷  Sign Up ⤷  Sign Up
Legacy Pharma Usa ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-002 Aug 29, 2002 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ZANAFLEX

See the table below for patents covering ZANAFLEX around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2005023252 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.